Introduction
============

Schizophrenia (SZ) is a common and disabling mental disorder with complex inheritance and an estimated heritability exceeding 80%.^[@bib1]^ Genome-wide association studies are beginning to identify common genetic variation accounting for a small fraction of the genetic risk and support the existence of a very large number of susceptibility loci.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib5]^ Many studies have demonstrated a strong selective disadvantage for SZ, the patients having on average half the number of offspring than the general population,^[@bib6],\ [@bib7],\ [@bib8]^ yet the frequency of the disease persists high at 1%. Not surprisingly, studies also implicate *de novo* mutations in SZ,^[@bib9],\ [@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15]^ which suggests constant replenishment of pathogenic alleles balancing the selection process. The frequent involvement of *de novo* mutations could be due, in part, to the large number of target genes involved in neurodevelopment. The development of the nervous system is an elaborate process involving the coordinated action of genes and their products to accomplish individual tasks such as the coordinated growth, migration and synapsing of neurons to form a system capable of cognitive processing. Although the biological processes accomplishing these tasks might be robust and tolerate mildly damaging variation, it is possible that accumulation of such variation in components of the same process, either by new mutation or by co-inheritance, can lead to significant neurodevelopmental defects and SZ. Although single deleterious mutations would be quickly cleared by selection, mildly deleterious variants that aggregate to cause disease would be resistant to selection because as their frequency becomes lower, their rate of co-occurrence is reduced exponentially and in most carriers they do not lead to a selective disadvantage.

Studies in cancer have shown that mutations in genes encoding components of several different cell proliferation pathways can produce similar tumor types.^[@bib16],\ [@bib17]^ Like cancer, SZ shows high phenotypic heterogeneity despite the commonalities responsible for considering it a single disease entity. As many processes are involved in neurodevelopment, disruption of any one might be sufficient to cause SZ. Where in cancer a second hit often occurs as a somatic mutation,^[@bib18]^ in the case of SZ all deleterious variants would need to be cotransmitted (which might include germline *de novo* events). For variants with relatively low allele frequencies, for example, below 10--15% each, this would be a rare event (for example, \<3% for two co-occurring variants, \<0.5% for three variants, and so on). In addition to their allowing persistence in the population, this could explain the small observed effect sizes, the small estimated fraction of explained heritability,^[@bib2]^ the extensive phenotypic heterogeneity of SZ and the difficulties in gene mapping. Our proposed model is illustrated in [Figure 1](#fig1){ref-type="fig"} and we refer to it as the pathway clustering model. What is important in testing this model is to know enough about the coordinated action of genes to perform a function to define the most concise group without missing important components.

Since being associated with SZ in 2002,^[@bib19],\ [@bib20]^ *NRG1* (encoding neuregulin 1) is among the most widely examined genes showing converging evidence of association in multiple studies.^[@bib21],\ [@bib22],\ [@bib23],\ [@bib24],\ [@bib25]^ The evidence has been expanding to include other genes involved in neuregulin (NRG) signaling. Our group has previously reported that variation in *NRG3* (neuregulin 3), a paralog of *NRG1*, is associated with the development of delusional symptomatology in SZ patients,^[@bib26]^ a finding replicated by other investigators.^[@bib27],\ [@bib28]^ Accumulating evidence from association studies also involves *ERBB4*, the gene encoding the main receptor for *NRG1* and *NRG3*,^[@bib29],\ [@bib30]^ and variation in *ERBB4* has been reported to interact with variation in *NRG1* increasing susceptibility to SZ.^[@bib31],\ [@bib32]^

NRGs are a family of signaling molecules with extracellular epidermal growth factor domains that bind to ERBB receptors to modulate neuronal migration and differentiation.^[@bib33]^ Two members, NRG1 and NRG3, have been linked to SZ and they share the receptor ERBB4. Studies on NRG1 have shown that once produced it is inserted in the cell membrane, where it can either signal solely to adjacent cells or be released through cleavage by β-secretase^[@bib34]^ ([Figure 1](#fig1){ref-type="fig"}). Following binding of the NRG1 epidermal growth factor domain, ERBB4 is either autophosphorylated or transphosphorylated (canonical forward signaling) or cleaved by γ-secretase to release the C-terminal intracellular domain, which can translocate to the nucleus and regulate transcription (non-canonical forward signaling). It has also been shown that NRG1 itself can be cleaved by γ-secretase with the C-terminal intracellular domain migrating to the nucleus in canonical backward signaling.^[@bib35],\ [@bib36],\ [@bib37]^ The components and relationships of the key players in the NRG signaling pathway (NSP) are illustrated in [Figure 1](#fig1){ref-type="fig"}. The 10 genes encoding these NSP components are the focus of our study. Evidence from mouse models supports our choice of genes and a role of β- and γ-secretase in SZ through NRG signaling. Mice lacking *BACE1*, encoding for β-secretase, exhibit SZ-like phenotypes.^[@bib38]^ Similarly, deficiency of *APH1B*, a component of γ-secretase, also causes neurobehavioral abnormalities similar to SZ.^[@bib39]^ In addition, altered levels of specific NRG1 mRNA transcripts and protein fragments have been reported in the prefrontal cortex and hippocampus of SZ patients, providing more evidence for dysregulated NRG1 processing.^[@bib40],\ [@bib41],\ [@bib42]^ We note that NRG3 has not yet been shown to be processed through the same mechanisms as NRG1; however, we include it in our analysis because of its close relationship to *NRG1* and its involvement in SZ.

Here, we explore our hypothesis of a pathway clustering model on the NSP, taking a narrow and stringent definition of pathway that includes only components known to be connected in a well-defined biological process. Predictions stemming from this model include that: (i) evidence of linkage (allele sharing) over the genes of the pathway will be weak but consistently elevated; (ii) families linked to one locus will also be linked to the other loci encoding components of the pathway; (iii) patients with damaging DNA variants in one gene will more often also have damaging variants in other genes of the same pathway; and (iv) the subgroup of patients with the NSP pathway affected will differ in phenotype from other patients.

Patients and methods
====================

SZ pedigrees
------------

We examined 123 multiplex families (that is, more than one affected family member) of European Caucasian background for which genome-wide linkage data are available and reported previously.^[@bib43]^ Details on the recruitment procedures are described in Blouin *et al.*^[@bib44]^ All individuals were interviewed using either a modified Diagnostic Interview Schedule^[@bib45]^ or the Diagnostic Interview for Genetic Studies (DIGS).^[@bib46]^ Diagnoses were made through a consensus procedure using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) consensus checklist criteria. We also evaluated nine factorial phenotypes derived from a principal component phenotypic analysis of 73 indicators, which has been previously described in detail.^[@bib47]^ These nine factors include the often-reported delusions, hallucinations, disorganization, negative, and affective factors and novel factors such as child/adolescent sociability, scholastic performance, disability/impairment and prodromal. All nine factors demonstrate significant familiality, with the highest scores for disability/impairment (0.61), disorganization (0.60) and scholastic performance (0.51).^[@bib47]^

The Johns Hopkins institutional review board has approved all recruitment methods and protocols for collection of clinical data and blood samples for this study and informed consent has been obtained from all individuals.

Linkage data analysis
---------------------

Genotyping, quality control procedures and linkage analysis results have been described previously.^[@bib43]^ We genotyped the 6008 single-nucleotide polymorphisms (SNPs) in the Illumina BeadArray Linkage mapping panel version 4.0 (Illumina, San Diego, CA, USA) at the Center for Inherited Disease Research at Johns Hopkins. We calculated the non-parametric linkage (NPL) scores across the genome for each family and for the whole set of pedigrees using the analysis software MERLIN.^[@bib48]^ Sample-wide NPL scores across the genome were used to extract the scores at the location of each of the 10 genes of interest and to obtain their average, which was then compared with the average scores of 100 000 random draws of 10 loci from across the genome. This method, which we have described and validated in simulated and real data, tests whether a set of loci is enriched for true linkage signals, regardless of their individual statistical significance.^[@bib49]^ For each gene, we identified the SNP within or closest to the gene in the linkage panel, which has a density of about one SNP every 500 kb, and the NPL score reported at that location was used for the analysis.

We used the individual family NPL scores at each of the 10 loci to examine pairwise correlations between linkage scores. These involved 123 cases (families) and 10 variables (loci). We hypothesized that if multiple hits in a pathway are involved, the families that show linkage at one locus are also more likely to show linkage at another, while the remaining families will show linkage at none. We considered NPL scores between −0.5 and +0.5 as uninformative and coded them as 0, otherwise positive scores were coded as 1 (evidence for linkage) and negative scores as −1 (evidence against linkage), regardless of their actual magnitude to remove biases due to family size. Owing to the lack of normal distribution, Kendall\'s tau (*τ*) coefficient was used to calculate linkage correlations between loci. The same was used to calculate correlations between the number of variants at one gene and the number of variants at the remaining pathway genes. These *P*-values are one-tailed since only positive correlations are consistent with the model and were validated by 1 000 000 permutations of the variant carriers for each gene (see [Supplementary Material](#sup1){ref-type="supplementary-material"}). To assess correlations between quantitative factor phenotypes and the load of variants in the NSP, we used a generalized linear model that included family ID as a categorical factor. This was preferred because we have shown that these factors show significant familial aggregation.^[@bib47]^ These tests were two-tailed as there is no *a priori* expected direction. All statistical analysis was performed using the software Statistica (StatSoft, Tulsa, OK, USA).

Sample pooling and exon sequencing
----------------------------------

We sequenced pairs of distant affected relatives, so that in addition to assessing clustering of variants in individuals, we could assess whether the same pathway is perturbed across the extended family. On the basis of the availability of affected distant relatives and regardless of linkage to the loci, we selected 24 pairs of relatives (48 SZ cases), the closest relationship being avuncular (25% expected genome sharing). The expected identity by descent due to relatedness was 0.25 for 12 pairs, 0.125 for 9 pairs, 0.0625 for 2 pairs and 0.03125 for 1 pair. We used next-generation technology to sequence all 120 protein coding exons (including alternative exons) of *NRG1* and *NRG3*, the NRG receptor gene *ERBB4*, the *BACE1* gene, which encodes β-secretase enzyme, and the six genes that encode the components of the γ-secretase multiprotein complex (*PSEN1*, *PSEN2*, *PSENEN*, *NCSTN*, *APH1A* and *APH1B*), totaling 38.9 kb of genomic sequence. We sequenced amplified DNA from pools of four subjects (12 pools in total) following the procedures reported by Niranjan *et al.*^[@bib50]^ with minor modifications. We aligned the reads to the reference human genome sequence (hg19 build) using the Bowtie alignment program,^[@bib51]^ and subsequently processed, sorted and indexed using SAMtools.^[@bib52]^ Variant identification was performed for each pool using the Integrated Genomics Viewer software (IGV 2.1, <http://www.broadinstitute.org/igv/>). We validated all identified coding variants and de-convoluted the pools by Sanger sequencing (detailed procedures in [Supplementary Material](#sup1){ref-type="supplementary-material"}).

Results
=======

Linkage over the 10 loci comprising the NSP
-------------------------------------------

We have previously demonstrated that testing the average linkage score across multiple loci and comparing it to the average of randomly selected loci is a powerful approach to show enrichment in true loci.^[@bib49]^ According to the pathway clustering model, we expect such enrichment across the 10 NSP genes. The individual NPL scores from our 123 multiplex pedigrees are as follows: *BACE1*, 1.92; *APH1A*, 1.70; *PSENEN*, 1.21; *NCSTN*, 1.17; *APH1B*, 0.96; *NRG1*, 0.92; *NRG3*, 0.12; *ERBB4*, −0.25; *PSEN2*, −0.44; and *PSEN1*, −0.59. The overall average is 0.67. To assess the significance of this combined linkage, we performed 100 000 draws of 10 loci at random from the same genome scan providing an empirical *P*=0.067, which, although not formally reaching significance, suggests that many of the 10 NSP genes may carry SZ risk alleles.

Correlation of linkage scores across SZ families
------------------------------------------------

According to our pathway clustering model, the subset of families with disrupted NSP function will show linkage to many NSP loci, while the other families to none, generating correlations of linkage scores between NSP loci. All pairwise correlations of linkage scores between the 10 NSP loci in our data are shown in [Table 1](#tbl1){ref-type="table"}. Two genes, *NCSTN* and *APH1A*, are located \<50 cM apart on the same chromosome; therefore; correlation of linkage is expected on this basis and should be disregarded (the *P*-value has been removed from [Table 1](#tbl1){ref-type="table"}). Of the 44 remaining comparisons, 28 showed positive and 16 negative correlations compared to an expected 22 of each (observed vs expected *χ*^2^ *P*=0.07). Two nominally significant negative correlations were observed, both for *NRG3* (not different from the 1.1 negative correlation expected by chance in 44 tests, underlined in [Table 1](#tbl1){ref-type="table"}). In contrast, six positive correlations were statistically significant (Kendall\'s rank correlation *P*\<0.05, bold and underlined in [Table 1](#tbl1){ref-type="table"}). The number of positive nominally significant results is almost sixfold higher than expected by chance (6 observed vs 1.1 expected; *χ*^2^ *P*=2.2 × 10^−6^), consistent with our model. As it could be argued that the positional correlation between *NCSTN* and *APH1A* makes the observations non-independent, we repeated the analysis removing all comparisons involving *APH1A* and this enrichment remained significant (*P*=7.2 × 10^−4^). This independent evidence from two different approaches prompted us to search for the responsible variants by sequencing all coding exons of the 10 NSP genes.

Clustering of damaging coding variants in the NSP
-------------------------------------------------

We applied next-generation sequencing on 24 pairs of distantly related affected subjects in 12 tagged pools of 4. We obtained on average 12 356 105 100-bp single-end reads from each indexed library and more than 75% of the reads mapped successfully to the hg19 human reference genome using Bowtie default parameters. The mean coverage for coding variants across all 12 libraries was 21 613 (median 21 504) reads, which resulted in an average read depth of 2702 reads per allele. To complete our screen, we sequenced all exons with \<20 × coverage per individual allele (2.6% of all exons) by Sanger sequencing in the respective pools.

All identified exonic variants are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. We detected 13 non-synonymous missense variants in 15 of the 24 pairs examined (62.5%). We validated all variants and de-convoluted the pools by conventional Sanger sequencing. Twelve variants were present in dbSNP135 and one, located in *APH1B* gene, was novel (p.Val199Leu). Characterization of the functional impact of coding variants using PolyPhen-2 and SIFT algorithms^[@bib53],\ [@bib54]^ predicted that 7 out of the 13 are potentially deleterious to protein function. All predicted damaging variants had minor allele frequencies below 0.12 except rs3924999 in *NRG1*, which had a minor allele frequency of 0.48. On the basis of our hypothesis as outlined in the introduction, we only considered for further analysis variants that had a minor allele frequency below 0.12 and were predicted to be damaging by at least one algorithm. These are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Our model predicts that potentially deleterious variants should cluster in certain SZ individuals/pedigrees, those where the disease is caused by disruption of the NSP. The question therefore is whether a SZ patient who has damaging variants in one NSP gene is more likely to also have damaging variants in the other NSP genes. We tested by Kendall\'s rank correlation analysis for correlations between the counts of variants in each gene compared with the count of variants in the remaining genes. This is a total of three tests, one for each of *NRG1*, *APH1B* and *NRG3*; *APH1A* was not tested because only two individuals carried the identified mutation, but was included when testing other genes. We found significant correlations for *NRG1* and *APH1B* (*τ*=0.23, *P*=0.01, and *τ*=0.28, *P*=0.002, respectively, one-tailed). *NRG3* showed a nonsignificant negative correlation. To account for within-family genotype correlations that might inflate the statistic (the 48 observations are not truly independent), we also performed the analysis on the average variant burden of the two relatives and the family as a unit. Despite reducing the observations to 24, we obtained similar strong results ([Table 2](#tbl2){ref-type="table"}).

The lack of positive correlations for *NRG3* was of interest as the link of this gene with β- and γ-secretase processing has not been shown. It is also interesting that *NRG3* did not show positive linkage correlations with other genes, wherewas when we tried removing it from the set of genes tested for their NPL average, the permutation *P*-value improved (*P*=0.053). Although *NRG3* is a paralog of *NRG1* and may share some pathway components, it may well function in a different or parallel pathway. For this reason, we performed the same analysis excluding *NRG3*. We observed marked improvement and high statistical significance of the correlations of variation in *APH1B* and *NRG1* with the remaining genes (*τ*=0.67, *P*=2.5 × 10^−6^, permutation *P*=1.7 × 10^−4^; *τ*=0.53, *P*=1.5 × 10^−4^, permutation *P*=3.4 × 10^−3^). This result, which remains significant after Bonferroni-based correction for removing each of the genes and re-testing, strongly supports our hypothesis and has potential implications for the possible relationship of *NRG3* to the NSP and its processing compared to *NRG1*. It is interesting to observe that while the carriers of the *NRG3* variant do not have more variants in other NSP genes, in four of the six families both affected members carry the damaging variant, despite the expected identity by descent sharing being 25% or less.

Phenotypic correlates of NSP damaging variants
----------------------------------------------

The pathway clustering model predicts that individuals with different affected pathways might differ in phenotype. The sequencing results above allow us to identify individuals whose SZ is likely due to variants in the NSP. The same individuals have been studied in a phenotype factor analysis that we have performed and published,^[@bib47]^ each having available scores for nine quantitative factors reflecting distinct clinical dimensions. We tested whether the NSP mutational load correlates with the each of the nine factor scores, the scores that are calculated for each individual based on the presence or absence of the 73 phenotypic indicators and their loadings on each factor. Since we have shown that the factors show familial aggregation,^[@bib47]^ for these factors we used a generalized linear model that included family ID as a categorical predictor. Owing to the sequencing results above questioning the inclusion of *NRG3* in the gene set, we performed this analysis with and without *NRG3*. We observed significant correlations with two of the nine factors that improved and increased to three when excluding *NRG3* variants ([Table 3](#tbl3){ref-type="table"}). The strongest result was for the impairment/disability factor (*P*=0.004), with lower disability in carriers of NSP damaging variants compared to patients with other pathways presumably affected. Of note, the presence of NSP damaging variants also predicted an elevated hallucination score when *NRG3* variants were not included in the analysis (*P*=0.028).

Discussion
==========

SZ is a complex multifactorial mental disorder likely caused by the synergistic effects of genetic and environmental influences.^[@bib2],\ [@bib55]^ As sample sizes have grown, genetic studies are detecting common polymorphic variants robustly associated with SZ in diverse ethnic populations, signifying that SZ is a highly polygenic disorder with multiple genetic loci involved.^[@bib2],\ [@bib4]^ In line with this notion, a recent hypothesis suggests that hundreds or even thousands of loci act together in the context of inter-related molecular pathways to confer liability to SZ.^[@bib56]^ Here, we further propose that in individual cases SZ may be the result of variants accumulating and perturbing the function of only one or a few of the many critical pathways. The specific pathway(s) may differ between patients, but might be similar within families. This model combines pathway heterogeneity and a requirement for multiple hits to the pathway. Its main difference from models commonly used in sequencing studies for rare variants is the prediction of heterogeneity among patients, which increases power and can be explored in a patient-only design. It further proposes that in addition to the number of damaging genetic variants, their distribution in pathway gene-sets is crucial, which could explain the difficulties of association and sequencing studies in identifying causative genetic loci. Directly testing this model will soon become possible with extensive exome and genome sequencing data combined with detailed and reliable delineation of the relevant pathways. In our study, we focus on one pathway well connected to SZ whose core components are well characterized and we consistently find support for the model.

There are two important aspects of our results, one regarding the NSP and another regarding the possibility that this model can be generalized. As others have previously suggested through association studies,^[@bib25],\ [@bib28],\ [@bib57]^ we now show through different approaches that multiple members of the NSP are involved in SZ. The increased linkage scores across the NSP gene-set, the correlations between linkage scores, the aggregation of potentially deleterious variants in a subset of patients and families and the phenotypic differences of these individuals strongly support the idea that multiple hits in the NSP increase the risk of SZ in a subset of individuals and families. We point to a few specific variants that should be the subject of functional follow-up including their possible biological interactions. There is little doubt that these variants are only a subset and that others, including non-coding or synonymous functional variants, could be involved. Further, our list of NSP genes may be incomplete and it appears from our results that *NRG3* should be removed. Having a reliable model will help identify such variants and new gene-set members in larger samples, having a significant impact on our knowledge of the role of the NSP in SZ etiology. It should be noted that our assumption of a linear relationship between NSP variant load and phenotype is admittedly an oversimplification, only applied for lack of enough data to explore the true underlying model. In our study 6 out of 24 families (25%) carry variants in multiple NSP genes and we find that carrying such variants leads to lower scores in the 'impairment/disability\' phenotypic factor (higher functioning) and higher scores in the 'hallucinations\' factor (more positive symptoms). This is of particular interest in view of results exploring NRG3 and showing an association with a subgroup of subjects with SZ who experience florid delusions and have relatively spared cognition.^[@bib27]^ Although our factor scores are only a statistical construct and the factor names simply derived from highly loading phenotypic items, there is a clear parallel emerging suggesting the NSP as a pathway associated with positive symptoms, relatively sparing cognition and retaining functional capacity.

The second aspect of these data is that they are consistent with a broad model of pathway heterogeneity and damaging variant clustering for SZ illustrated in [Figure 2](#fig2){ref-type="fig"}. This pathway clustering model can be exploited for the analysis of forthcoming large-scale sequencing data on SZ cases and controls. Although we have not shown that other pathways behave in the same way, the NSP provides a paradigm. In fact, a likely scenario might involve more than one biological process per pathway and more than one pathway per affected individual, in a nested clustering model that future large patient sequencing data sets will make possible to explore. Today few other pathways combine the connections to SZ and the biological knowledge available for NRG. Possible candidates include RELN,^[@bib58]^ DISC1-interacting proteins^[@bib59]^ and pathways emerging from large collaborative genome-wide association studies.^[@bib60]^ Statistical models based on the pathway heterogeneity hypothesis applied on forthcoming larger data sets with increased statistical power can test networks of genes revealed from proteomics,^[@bib61]^ gene expression experiments and gene ontology databases. Exploratory analyses could help refine these networks, greatly improving our knowledge of the disease.

While our results are positive and consistent, it is important to keep in mind the limitations of each approach. Linkage information is well known to be inherently noisy, especially when the number of families is relatively small. While our test across loci approaches significance, the individual NPL scores should be considered with caution. The same is true for positive correlations between linkage scores, which are found in highly significant excess but are hard to assess individually. Further, it cannot be assumed that we detected all deleterious variants or all the variants we analyzed are in fact deleterious. Some of our predicted functional variants could be mischaracterized and others missed, together with all functional variants in non-coding regions. This could explain why some genes in which we found no variants show strong linkage scores and correlations. Finally, as we noted it is more than likely that the conservatively selected set of NSP genes is incomplete or inaccurate. For example, *NRG3* perhaps should be examined independently from *NRG1*.

Overall, in this work we explore the NSP and find that it shows aggregation of potentially damaging genetic variation in a subset of SZ patients and families. This result leads us to propose a model of pathway clustering, where multiple hits in one of many possible pathways explains SZ in a subset of cases. Exploring this possibility could lead to a much better understanding of disease risk and genetic heterogeneity, and also provide a framework for more successful analytical approaches.
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![Schematic of neuregulin-ERBB4 signaling showing the roles of the products of the selected genes. The γ-secretase multiprotein complex is constructed from the products of the genes: *PSEN1*, *PSEN2*, *APH1A*, *APH1B*, *PSENEN* and *NCSTN*. The cleavage of NRG3 by *BACE1* is hypothesized and has not been shown experimentally.](tp201333f1){#fig1}

![Pathway clustering model. Schematic representation of the proposed pathway clustering model for schizophrenia demonstrating how clustering of multiple protein damaging variants within different well-defined molecular pathways could represent an unrecognized factor of SZ risk and phenotypic heterogeneity.](tp201333f2){#fig2}

###### Pairwise correlations between linkage signals across 123 multiplex schizophrenia families

  **GENE**       **NCSTN**   **PSEN2**         **APH1A**   **PSEN1**         **APH1B**         **PSENEN**   **BACE1**         **NRG1**   **NRG3**       **ERBB4**
  -------------- ----------- ----------------- ----------- ----------------- ----------------- ------------ ----------------- ---------- -------------- -----------
  ***NCSTN***                **[0.17]{.ul}**               [**0.12**]{.ul}   **[0.15]{.ul}**   0.05         **[0.17]{.ul}**   −0.06      0.04           0.08
  ***PSEN2***    **0.005**                     **0.12**    0.04              0.00              0.12         0.07              −0.01      −[0.17]{.ul}   0.06
  ***APH1A***                **0.046**                     0.05              0.07              −0.06        **[0.13]{.ul}**   0.00       0.08           0.07
  ***PSEN1***    **0.046**                                                   0.07              0.03         −0.09             0.05       −0.01          0.02
  ***APH1B***    **0.014**                                                                     0.02         −0.06             −0.03      0.01           −0.01
  ***PSENEN***                                                                                              0.07              −0.05      −[0.13]{.ul}   −0.01
  ***BACE1***    **0.006**                     **0.028**                                                                      −0.03      0.03           0.01
  ***NRG1***                                                                                                                             −0.05          0.03
  ***NRG3***                 0.005                                                             0.036                                                    0.00
  ***ERBB4***                                                                                                                                            

Kendall\'s *τ* coefficient is shown above the diagonal, with nominally significant correlations underlined and those that are positive in bold. Nominally significant *P*-values are below the diagonal and if the correlation is positive they are in bold. The *P*-value for the linked loci NCSTN--APH1A has been removed.

###### Correlations between the number of damaging variants in each gene, with the number of variants in the remaining NSP genes

                              *Individuals (*N=*48)*   *Families (*N=*24)*           
  --------------------------- ------------------------ --------------------- ------- --------------
  *NRG1* vs other             0.23                     0.010                 0.31    0.016
  *APH1B* vs other            0.28                     0.002                 0.33    0.011
  *NRG3* vs other             −0.17                    NA                    −0.24   NA
                                                                                      
  *Excluding NRG3 variants*                                                          
  * NRG1* vs other            0.34                     3.6 × 10^−4^          0.53    1.5 × 10^−4^
  * APH1B* vs other           0.50                     2.8 × 10^−7^          0.67    2.5 × 10^−6^

Abbreviations: NA, not applicable; NRG, neuregulin; NSP, neuregulin signaling pathway; SZ, schizophernia.

Rare variant correlations for each gene with the remaining NSP genes based on 48 SZ cases. To account for familial genotype correlations, results are also shown for the average variant load of each pair (24 observations). The lower two lines show the results after excluding *NRG3* from the NSP (see text).

###### Differences in symptom dimensions between those SZ cases that carry NSP damaging variants and those that do not

  *Factor*                       *Number of NSP variants*   *Excluding NRG3*   *NRG3 alone*                     
  ------------------------------ -------------------------- ------------------ -------------- ----------- ----- -------
  Negative symptoms                                         0.586                             0.376             0.623
  Affective symptoms                                        0.982                             0.944             0.859
  Disorganization                                           0.420                             0.490             0.677
  Prodromal signs                                           0.706                             0.874             0.613
  Delusions                                                 0.231                             0.521             0.183
  Scholastic functioning                                    0.791                             0.444             0.386
  Child/adolescent sociability   (−)                        **0.034**          (−)            **0.015**   (−)   0.998
  Impairment/disability          (−)                        **0.018**          (−)            **0.004**   (+)   0.850
  Hallucinations                 (+)                        0.141              (+)            **0.028**   (−)   0.380

Abbreviations: NRG, neuregulin; NSP, neuregulin signaling pathway; SZ, schizophernia.

The effect of NSP damaging variants on the phenotype is measured through correlations between NSP variant load and factorial dimension scores (see text). The direction of the effect is only shown for significant *P*-values which are shown in bold.
